Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
This study is ongoing, but not recruiting participants.
Study NCT01101880 Information provided by University of Washington
First Received on April 8, 2010. Last Updated on May 22, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Additional conditions recognized in this trial
Anemia
Anemia, Refractory
Anemia, Refractory, with Excess of Blasts
Congenital Abnormalities
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Myeloproliferative Disorders
Neoplasms
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Precancerous Conditions
Interventions listed in this trial
filgrastim
clofarabine
cytarabine
Additional drug interventions recognized in this trial
Lenograstim
More general drug interventions related to this trial
Adjuvants, Immunologic
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Washington
National Cancer Institute (NCI)
Back to top of Main Content
